AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44-24
E-Mail: nina.roth@aoporphan.com
Contact:
AOP
Phone: +43 503 72 44-24
E-Mail: nina.roth@aoporphan.com
KEYWORDS:
- Polycythaemia Vera
- FDA
- Ropeginterferon?alfa-2b
- BESREMi®
attachments to announcement
BESREMi® (Ropeginterferon?alfa-2b) deemed safe and efficacious by the US FDA
back to announcementphotos
 [ download press photo ] | title: Dr Widmann image text: Dr Widmann copyright: AOP Orphan Pharmaceuticals AG / Natascha Unkart & Isabelle Köhler |
